Omeros Corporation (OMER)

Over the past six months, Omeros Corp. experienced several stock events. The company reported a significant turnaround in late 2025, driven by a major asset sale and its first U.S. drug approval. The Q4 2025 results reflected a net gain from the zaltenibart transaction with Novo Nordisk. The company achieved FDA approval and U.S. launch of YARTEMLEA for TA-TMA, with commercial sales beginning in January 2026. Proceeds from the Novo Nordisk deal were used to reduce debt. Omeros Corporation filed a follow-on equity offering in November 2025. Analysts have issued various ratings and price target adjustments. As of April 10, 2026, the stock price was $11.50, up 70.88% over the period from April 11, 2025, to April 10, 2026.

Based on historical stock price data, Omeros Corp. exhibits some demand seasonality in its stock performance. November has the highest probability of positive returns, making it a potentially strong month for investment. April also suggests a favorable period. Conversely, September has the lowest probability of positive returns.

Omeros Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various disorders within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. The company addresses large-market and orphan indications, particularly targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its major products and pipeline candidates include Narsoplimab (OMS721/MASP-2), OMS1029, Zaltenibart, OMS527, YARTEMLEA, and several preclinical programs.

Omeros Corporation is headquartered in Seattle, Washington, United States, and has expanded its operations to include research and development facilities in both the United States and Europe to support its global clinical trials and regulatory activities.

Omeros Corporation's brand reputation over the past year appears to be generally positive, largely driven by its scientific advancements and strategic business moves. The company has been recognized for its innovative therapeutic offerings and a robust pipeline. The FDA approval and U.S. launch of YARTEMLEA, along with the significant licensing deal with Novo Nordisk, have been highlighted as transformative events. The consensus among analysts is a "Moderate Buy" or "Strong Buy" rating. The company faces challenges inherent in clinical-stage biopharmaceutical development.

Omeros Corporation's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock. Retail investors possess a significant portion, giving them considerable influence over company decisions. Insiders own a portion of the company's stock, with CEO Gregory Demopulos owning a notable percentage.